Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Astellas Pharma, Inc. (OTC: ALPMY).

Full DD Report for ALPMY

You must become a subscriber to view this report.


Recent News from (OTC: ALPMY)

FDA Approves Supplemental New Drug Application for Myrbetriq® (mirabegron) for Use in Combination with solifenacin succinate for the Treatment of Overactive Bladder Symptoms
TOKYO , May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combin...
Source: PR Newswire
Date: May, 07 2018 21:00
3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: May, 05 2018 08:54
First Eagle Global Value Team Quarterly Commentary Q1 2018
Read more ...
Source: SeekingAlpha
Date: May, 03 2018 03:02
Astellas Pharma Inc. ADR reports FY results
Astellas Pharma Inc. ADR ( OTCPK:ALPMY ): FY Core profit of ¥204.32B Revenue of ¥1300.3B (-0.9% Y/Y) Press Release More news on: Astellas Pharma, Inc. ADR, Astellas Pharma, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: April, 26 2018 01:13
Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
TOKYO , April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas" ) today announced that it submitted on March 23, 2018 , a new drug application (NDA) for marketing approval of gilteritinib (generic name) in Japan for the tre...
Source: PR Newswire
Date: April, 23 2018 21:00
Key events next week - healthcare
Noteworthy events for the week of April 22 - 28 for healthcare investors. More news on: Navidea Biopharmaceuticals, Galectin Therapeutics, Inc., Eli Lilly and Company, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 20 2018 07:43
Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company
TOKYO , April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan , "Kite"), today announced that an agreement has been completed for the transfer of...
Source: PR Newswire
Date: April, 18 2018 18:00
3 Things In Biotech, March 27: Roche Rips, Loxo Rolls, Astellas Rams
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 28 2018 08:00
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash. , March 26, 2018 /PRNewswire/ --  Astellas Pharma Inc.  (TSE: 4503, President and CEO: Yoshihiko Hatanaka , "Astellas") and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrou...
Source: PR Newswire
Date: March, 26 2018 08:00
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
NEW YORK and TOKYO , March 19, 2018 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , "Astellas") announced today that a supplemental New Drug Application (sNDA) for XTANDI ® (enzalutamide) has been accepted ...
Source: PR Newswire
Date: March, 19 2018 16:15

 


About Astellas Pharma, Inc. (OTC: ALPMY)

Logo for Astellas Pharma, Inc. (OTC: ALPMY)

Not available

 

Contact Information

 

 

Current Management

  • Masao Yoshida / CEO, President

Current Share Structure

     


    Recent Filings from (OTC: ALPMY)

    Filing to become effective immediately upon filing
    Filing Type: F-6EFFiling Source: edgar
    Filing Date: December, 21 2017
    Post-effective amendment to a previously filed F-6
    Filing Type: F-6 POSFiling Source: edgar
    Filing Date: September, 29 2017

     

     


    Daily Technical Chart for (OTC: ALPMY)

    Daily Technical Chart for (OTC: ALPMY)


    Stay tuned for daily updates and more on (OTC: ALPMY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: ALPMY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    OTC Report
    @OTCReporter

     

     


    Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of ALPMY and does not buy, sell, or trade any shares of ALPMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/